A Pilot Study to Determine Optimal Procedure Steps to Obtain and Maintain Uterine Artery Occlusion With the D-UAO Device

Uterine Fibroids Clinical Trial

Official title:

A Pilot Study to Determine the Optimal Procedure Steps to Obtain and Maintain Bilateral Uterine Artery Occlusion Using the GYNECARE GYNOCCLUDE™ Doppler Guided Uterine Artery Occlusion Device in Women With Uterine Fibroids

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01140555
• Other study ID #: 300-09-007
• Status: Terminated
• Phase: N/A
• First received: June 8, 2010
• Last updated: February 16, 2011
• Start date: April 2010
• Est. completion date: July 2010

Study information

• Verified date: February 2011
• Source: Ethicon, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Austria: Federal Office for Safety in Health CareGermany: German Institute of Medical Documentation and InformationNorway: Directorate of HealthNetherlands: Medical Ethics Review Committee (METC)
• Study type: Interventional

Clinical Trial Summary

This pilot study has a sequential design involving three groups to ensure appropriate development and evaluation of the optimal procedural steps of the D-UAO device and to confirm that those steps are reproducible in the hands of multiple surgeons.

Description:

1. Group 1 - beginning with the use of the current instructions for use (IFU) will have adjustments made as necessary to the D-UAO procedural steps for uterine artery occlusion confirmed by 2/3-D Power Colour Doppler ultrasound (2/3DPD).

2. Group 2 - verify that optimal D-UAO IFU procedural steps generated in Group 1 as confirmed by 2/3DPD.

3. Group 3 - verify that the optimal D-UAO procedural steps are reproducible in the hands of multiple surgeons in addition to the group 1 investigators, as confirmed by 2/3DPD.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2
• Est. completion date: July 2010
• Est. primary completion date: June 2010
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 25 Years to 55 Years

Eligibility

Inclusion Criteria:

• Age 25-55 years with regular menses and at least one symptom related to uterine fibroids (for example heavy bleeding).

• Completed child-bearing.

• At least one uterine fibroid of 3 cm diameter or greater with a prevailing pathology (e.g. as opposed to adenomyosis) of fibroids determined through abdominal/transvaginal ultrasound.

• Confirmation of the ability to clearly visualise bilateral uterine arteries with 2/3DPD.

• Dominant fibroid (defined as >3cm in diameter) must be well vascularised as determined by CE-MRI (for Group 2 and 3 patients only).

• Able to tolerate the required prolonged supine position during treatment (approximately 6 hours).

• Cervix suitable for tenaculum placement as determined by pelvic exam.

• Normal Pap smear within the last 36 months.

• Agrees to participate in the study, and following review of the patient information sheet documents this agreement by signing the Ethics Committee approved informed consent.

Exclusion Criteria:

• Prior endometrial ablation, uterine artery embolization, or uterine artery ligation.

• Pregnancy (As confirmed by a urine pregnancy test at screening and immediately prior to procedure).

• One or more lower uterine segment fibroids determined through pelvic exam which in the examiner's opinion would prevent proper clamp application.

• Any known contraindications to the contrast agent to be used for the CE-MRI as determined by the study radiologist (for Group 2 and 3 patients only).

• Pelvic mass outside the uterus suggesting other disease processes.

• An intrauterine device (IUD) in place during the day of procedure.

• Hydronephrosis as determined by interpretation of a pre-procedure renal ultrasound.

• No ureteral jets observed on ultrasound prior to clamping.

• Presence of a pedunculated fibroid determined by ultrasound, hysteroscopy, or saline infused sonography or CE MRI.

• Any current acute or chronic systemic infection or localized pelvic infection, including an unresolved urinary tract infection.

• Clinical history of any thromboembolic disease.

• History of gynecologic malignancy, atypical endometrial hyperplasia, or pelvic inflammatory disease.

• Using anticoagulation therapy (except OTC treatments, e.g. aspirin), or has a known underlying bleeding disorder.

• In the investigator's opinion, any medical condition or psychiatric illness that could potentially be life threatening or affect their ability to complete the study visits according to this protocol.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Leiomyoma
• Uterine Fibroids

Intervention

Device:
• GYNECARE GYNOCCLUDE™
GYNECARE GYNOCCLUDE™ Doppler Guided Uterine Artery Occlusion Device

Locations

Country	Name	City	State
Austria	Allgemeines Krankenhaus, Abteilung für Gynäkologie und Geburtshilfe	Linz
Germany	Frauenklinik, Universitatsklinikum Erlangen	Erlangen
Netherlands	Vrije Universiteit medisch centrum (VU Medical Center), Dept of Obstetrics and Gynaecology	Amsterdam
Norway	Ullevaal University Hospital, Department of Obstetrics & Gynaecology	Oslo

Sponsors (1)

Lead Sponsor	Collaborator
Ethicon, Inc.

Countries where clinical trial is conducted

Austria,  Germany,  Netherlands,  Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Optimal procedural steps	Establish and verify optimal procedural steps to obtain and maintain bilateral uterine artery occlusion using the GYNECARE GYNOCCLUDE™ Doppler Guided Uterine Artery Occlusion Device (D-UAO) for 6 hours, and confirm that these optimal procedural steps are reproducible by multiple surgeons	6 hrs	No
Secondary	Fibroid devascularization	Evaluation of the actual and percentage change in the uterine volume, dominant fibroid volume, T2 frequency, contrast enhancement index in the dominant fibroid and the number of patient with complete infarction of all fibroid tissue obtained from a comparison of the baseline and 1 month contrast enhanced MRIs.	Baseline and 1 month post procedure	No
Secondary	Safety	Incidence of patients with adverse events that result in the following: ureteral stenting, intra-operative or post operative blood transfusion, device related hospitalization >24hours, interventional treatment for fibroids within 1 month of the D-UAO procedure, DVT or PE, life threatening cardiac or respiratory arrest or other life threatening events	Baseline through one month post procedure	Yes